Patient advocate Austin Leclaire, who died Feb. 1, played a pivotal role in spurring the development of the first medicines ...
Despite the obstacles, Riley Herrera had a life filled with family, sports, travel, faith and hope before his death on Nov.
Robert Davidson is the first UK patient recruited to a new medical trial looking to support children with heart failure ...
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released topline results from its Phase 2 FIGHT DMD trial. The study evaluated ...
Contrary to prior data, this study shows that neither eosinophils nor STAT6-mediated IL-4/IL-13 signaling contribute ...
Cumberland Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug has improved the amount of blood pumped by the heart, ...
At just 15 years old, Ragheeb has already made a tremendous impact on his community as an ambassador for Capes for Kids, an ...
Stockhead on MSN1d
Health Check: Percheron ‘closes the book’ on failed childhood rare disease programCEO Dr James Garner says at the time of the December 18 trial bombshell that knocked 85% off the value of Percheron shares, ...
Edgewise Therapeutics , Inc. (NASDAQ:EWTX), with a market capitalization of $2.67 billion, is a biopharmaceutical company focused on developing innovative therapies for severe, rare muscle disorders.
GlobalData on MSN1d
Cumberland Pharmaceuticals reports data from trial of ifetroban for DMDCumberland Pharmaceuticals has reported positive outcomes from a trial of ifetroban as a potential treatment for Duchenne ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback